Solide Tumore

A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH, EudraCT Nummer: 2017-003496-54)

Indikation: Erstdiagnose Bauchspeicheldrüsenkrebs (Pankreskarzinom)

A multicenter phase I/II study of sequential epigenetic and immune targeting in combination with nab-Paclitaxel / Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (SEPION, EudraCT Nummer: 2017-001625-40)

Indikation: Erstdiagnose Bauchspeicheldrüsenkrebs (Pankreaskarzinom)

Prognostic role of circulating tumor DNA in resectable pancreatic cancer

Indikation: Primär resektables Pankreaskarzinom

Epidemiological study to monitor study participants with resected Stage II (high risk) or Stage III colorectal cancer for circulating tumor DNA before, during and after their treatment with adjuvant chemotherapy (NCT04813627)

Indikation: Pat mit operiertem CRC Stadium II+RF/III hinweisen

(RF: T4, Grade >=3, clinical presentation with obstruction/perforation, histological signs of vascular or lymphatic or perineural invasion, less than 12 lymph nodes examined)

A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (EudraCT Nummer 2020-000451-12)

Indikation: ctDNA positive Pat mit operiertem CRC Stadium II+RF/III

(RF: T4, Grade >=3, clinical presentation with obstruction/perforation, histological signs of vascular or lymphatic or perineural invasion, less than 12 lymph nodes examined)

A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients (RAMTAS, EudraCT Nummer: 2017-004162-99)

Indikation: Metastasierter Darmkrebs nach Durchlaufen der Standardtherapie

A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280-007, EudraCT Nummer: 2021-001309-60)

Open-label, Multicentre, Phase Ib/II Study of MEN1611, a PI3K Inhibitor, and Cetuximab in Patients With PIK3CA Mutated Metastatic Colorectal Cancer Failing Irinotecan, Oxaliplatin, 5-FU and Anti-EGFR Containing Regimens (MEN1611-02, EudraCT Nummer: 2019-003727-38 )

A Randomised Study to Assess the Efficacy of Cetuximab Rechallenge in Patients With Metastatic Colorectal Cancer (RAS Wild-type) Responding to First-line Treatment With FOLFIRI Plus Cetuximab (FIRE-4, EudraCT Nummer: 2014-003787-21)

Impact of a Centralized Tumour Board on Secondary Intervention Rate in Patients With RAS Mutant Metastatic Colorectal Cancer After First-line Treatment With FOLFOXIRI Plus Bevacizumab (FIRE-7, NCT Identifier: NCT04852250)

Indikation: Erstdiagnose Darmkrebs, Evaluation Resektabilität nach 4 Zyklen FOLFOXIRI + Bevacizumab.

Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer (FIRE-8, EudraCT Nummer: 2019-004223-20)

Indikation: Metastasierter Darmkrebs nach Durchlaufen der Standardtherapie

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer (FIRE-9, EudraCT Nummer: 2020-006144-18)

Indikation: Systemtherapie vs BSC nach Metastasenresektion beim Darmkrebs

A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or an Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer (CA209-8HW, EudraCT Nummer: 2018-000040-26)

Indikation: Erstdiagnose Darmkrebs mit Mikrosatelliteninstabilität

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC, Registry Identifier CTRP: NCI-2016-01417)

Indikation: Adjuvante Therapie (nach Operation) bei Darmkrebs mit einem DNA-Reparatur-Mechanismusdefekt

Nicht-interventionelle Biomarker-Studie zur molekularen Auswertung von konserviertem Tumorgewebe bei Patienten mit Magenkarzinom (AMG 199 201 80 293)

Indikation: Biomarkerstudie. Metastasierter Magen-, Bauchspeicheldrüsen-, und Darmkrebs nach Durchlaufen der Standardtherapie

A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (AMG 199,, EudraCT Nummer: 2019-002708-42)

Indikation: Metastasierter Magen-, Bauchspeicheldrüsen-, und Darmkrebs nach Durchlaufen der Standardtherapie

A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy (CUPISCO, EudraCT: 2017-003040-20)

Indikation: Erstdiagnose Cancer of Unknown Primary (Krebserkrankung mit unbekanntem Primärtumor)